C
Carlos Garcia-Echeverria
Researcher at Novartis
Publications - 177
Citations - 17035
Carlos Garcia-Echeverria is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Kinase. The author has an hindex of 58, co-authored 177 publications receiving 16339 citations. Previous affiliations of Carlos Garcia-Echeverria include University of Wisconsin-Madison & University of Michigan.
Papers
More filters
Journal ArticleDOI
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman,Jeffrey A. Engelman,Liang Chen,Xiaohong Tan,Katherine Crosby,Alexander R. Guimaraes,Rabi Upadhyay,S. Michel Maira,Kate McNamara,Samanthi A. Perera,Youngchul Song,Lucian R. Chirieac,Ramneet Kaur,Angela Lightbown,Jessica Simendinger,Timothy Q. Li,Robert F. Padera,Carlos Garcia-Echeverria,Ralph Weissleder,Umar Mahmood,Lewis C. Cantley,Lewis C. Cantley,Kwok-Kin Wong +22 more
TL;DR: In vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.
Journal ArticleDOI
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira,Frédéric Stauffer,Josef Brueggen,Pascal Furet,Christian Schnell,Christine Fritsch,Saskia M. Brachmann,Patrick Chène,Alain De Pover,Kevin Schoemaker,Doriano Fabbro,Daniela Gabriel,Marjo Simonen,Leon Murphy,Peter Finan,William R. Sellers,Carlos Garcia-Echeverria +16 more
TL;DR: The preclinical data show that NVP-BEZ235 is a potent dual PI3K/mTOR modulator with favorable pharmaceutical properties, and the compound was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer agents when used in in vivo combination studies.
Journal ArticleDOI
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
Violeta Serra,Benjamin Markman,Maurizio Scaltriti,Pieter Johan Adam Eichhorn,Vanesa Valero,Marta Guzman,Maria Luisa Botero,Elisabeth Llonch,Francesco Atzori,Serena Di Cosimo,Michel Maira,Carlos Garcia-Echeverria,Josep Lluis Parra,Joaquín Arribas,José Baselga +14 more
TL;DR: NVP-BEZ235 inhibits the PI3K/mTOR axis and results in antiproliferative and antitumoral activity in cancer cells with both wild-type and mutated p110-alpha, suggesting that skin may serve as surrogate tissue for pharmacodynamic studies.
NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, PreventsPI3K Signaling and Inhibitsthe Growth of Cancer Cellswith Activating PI3K Mutations
Violeta Serra,Ben Markman,Maurizio Scaltriti,Vanesa Valero,M. Guzman,Maria Luisa Botero,Elisabeth Llonch,Francesco Atzori,Michel Maira,Carlos Garcia-Echeverria,Josep Lluis Parra,Joaquín Arribas +11 more
TL;DR: NVP-BEZ235, a dual inhibitor of the PI3K and the downstream mammalian target of rapamycin (mTOR), was shown to have antiproliferative and antitumoral activity in cancer cells with both wild type and mutated p110-A as mentioned in this paper.
Journal ArticleDOI
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Constantine S. Mitsiades,Nicholas Mitsiades,Nicholas Mitsiades,Ciaran J. McMullan,Vassiliki Poulaki,Vassiliki Poulaki,Reshma Shringarpure,Masaharu Akiyama,Teru Hideshima,Dharminder Chauhan,Marie Joseph,Marie Joseph,Towia A. Libermann,Towia A. Libermann,Carlos Garcia-Echeverria,Mark A. Pearson,Francesco Hofmann,Kenneth C. Anderson,Andrew L. Kung +18 more
TL;DR: NVP-ADW742 monotherapy or its combination with cytotoxic chemotherapy had significant antitumor activity in an orthotopic xenograft MM model, providing in vivo proof of principle for therapeutic use of selective IGF-1R inhibitors in cancer.